阿尔凯默斯 ALKS 深 沪
等待开盘 07-18 09:30:00 美东时间
52.72
+0.780
+1.50%
华盛通- 最 高52.785
- 今 开51.06
- 成交量 171.37万股
- 最 低 50.94
- 昨 收 51.94
- 总市值 87.87亿
- 52周最高 55.67
- 市盈率 静 36.81
- 换手率 1.03%
- 52周最低 25.165
- 委 比 -68.14%
- 总股本 1.67亿
- 历史最高 79.041
- 量 比 1.01
- 振 幅 3.55%
- 历史最低 10.311
- 每 手 1
- 风险率 6.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 花旗上调苹果、西部数据、希捷科技、超微电脑等目标价；高盛上调蔚来"买入"评级，目标价7美元
今日重点评级关注：HC Wainwright & Co.：维持艾吉纳斯"买入"评级，目标价从23美元升至30美元；富国银行：上调Q32 Bio评级至"超配"，目标价66美元
07-14 11:36
Alkermes Says Lead Drug Maintains Wakefulness Benefits in Long-Term Narcolepsy Study
Alkermes plc (NASDAQ:ALKS) reported positive interim results from its ongoing long-term extension (LTE) study of investigational oral therapy alixorexton, showing sustained improvements in wakefulness, daytime sleepiness, cognition, and fatigue in adults with narcolepsy type 1 (NT1) and narcolepsy t...
07-13 23:06
JP Morgan Reinstates Neutral on Alkermes, Announces $60 Price Target
JP Morgan analyst Jessica Fye reinstates Alkermes (NASDAQ:ALKS) with a Neutral and announces $60 price target.
07-13 19:00
Alkermes Terminates VIVITROL Authorized Generic Supply Agreement With Amneal Without Penalties
On July 6, 2026, Alkermes plc (the "Company") and Amneal Pharmaceuticals LLC ("Amneal") terminated the previously disclosed Authorized Generic Product Supply Agreement entered into on September 9, 2025 (the "Agreement"). Capitalized terms used and not otherwise defined herein shall have the meanings...
07-08 20:10
美银称 Alkermes 即将公布的最新进展或使其食欲素相关业务价值面临风险
美国银行证券发布研报，针对阿尔凯默斯（ALKS）的投资价值作出调整，此前该公司股价因同赛道竞品收购完成已获得重估，但后续食欲素相关研发进展可能侵蚀其食欲素业务的...
06-30 10:37
美股大行评级 | 康托·菲茨杰拉德大幅上调AMD、英特尔、迈威尔科技、美光、西部数据目标价！Applied、INIO、LFTO、Quantinuum获多家大行首予买入评级
今日重点评级关注：Evercore ISI集团：维持ProQR Therapeutics"跑赢大市"评级，目标价从5美元升至6美元；摩根士丹利：维持霍尼韦尔"标配"评级，目标价从245美元升至490美元
06-30 10:14
This Liquidia Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. B of A Securities analyst Allen Lutz downgraded Doximity Inc (NYSE:DOCS) from Buy to Underperform...
06-29 20:49
美国银行证券将Alkermes评级下调至跑输大盘 设定38美元目标价
美国银行证券将生物制药企业阿尔凯默斯（Alkermes）的股票评级下调至“跑输大盘”，设定目标价38美元。 本次调整属于该行近期多板块评级下调趋势中的操作，此前...
06-29 20:23
B of A Securities Downgrades Alkermes to Underperform, Announces $38 Price Target
B of A Securities analyst Jason Gerberry downgrades Alkermes (NASDAQ:ALKS) from Neutral to Underperform and announces $38 price target.
06-29 20:01
Alkermes PLC：富国银行将目标价从44美元上调至65美元
富国银行将Alkermes（阿尔凯姆斯）的目标价从44美元上调至65美元。 译文内容由第三方软件翻译。 声明：市场有风险，投资需谨慎。本文由AI大模型基于公开信...
06-29 18:27
